How Combining Structurally Different RAF Inhibitors Can Open New Strides In Targeted Melanoma Therapy
Share This:
                           

About The Author

After graduating in Biochemistry from the University of Leipzig, Germany, in 2001 I started my PhD in the Clinical Cooperation Group Molecular Oncology at the University of Munich, Germany, where I developed novel proteomic approaches to investigate new tumour markers for head and neck carcinomas. In 2006, I moved to the Beatson Institute for Cancer Research, Glasgow, UK, as a post-doctoral researcher, where I investigated cancer related cellular signalling pathways using proteomics. I joined Systems Biology Ireland as a postdoctoral researcher in SBI in 2009 and currently lead SBI’s Melanoma Research Group. My main focus is the analysis of crucial signalling complexes responsible for resistance mechanisms in malignant melanomas.

                       

How Combining Structurally Different RAF Inhibitors Can Open New Strides In Targeted Melanoma Therapy

Malignant melanoma is a skin cancer primarily caused by overexposure to UV rays from the sun or tanning beds. Unfortunately, the number of skin cancers worldwide has increased dramatically over the past decades. The main factors for this trend are simply poor practice when protecting the skin from the sun, the extensive use of tanning beds, skin type, and the increase of people traveling abroad to spend their holidays in the sun. Due to its tendency to spread rapidly and...

Read more